Validation of a novel biomarker like IGFBP4 may facilitate the creation of customized treatment plans to normalize IGFBP4 levels, consequently leading to an improvement reflected by OSA remission. The gene discussed is IGFBP4; the disease is obstructive sleep apnea syndrome.